Profile: Transgene Biotek Limited provides drugs. We also provide human vaccines, tissue culture products and drugs for the treatment of cancer. We have developed a strategy that involves the use of monoclonal antibodies to target potent cytotoxic agents to multiple myeloma & esophageal adeno-carcinoma. Here, an antibody specific for cell surface antigen is covalently linked to a potent cytotoxic agent that is used as an immuno-conjugate drug. Injected immuno-conjugate drug specifically binds to the cell surface antigen on cancer cells followed by internalization of the antigen-antibody complex to ensure focused delivery & release of the conjugated cytotoxic drug inside the tumor cells, followed by the lysis of the cell. Immuno-conjugate chemotherapy is a clinically validated strategy, exemplified by gemtuzumab ozogamicin (GO), a humanized anti-CD33 antibody conjugated with the cytotoxic drug calicheamicin & approved for the treatment of relapsed acute myeloid leukaemia. A similar strategy is used for the development of two specific immuno-conjugate cancer drugs, targeting multiple myeloma and esophageal adeno-carcinoma. Tumor targeted delivery of the cytotoxic drug not only maximizes its antitumor efficacy, but also significantly reduces its exposure to normal tissues, thereby improving its therapeutic index. This strategy of tumor-targeted chemotherapy is therapeutically more advantageous than the traditionally used chemotherapeutic strategy.